RNS - upper end of guidance5 Nov 2024 07:07
Revenues are tracking towards the upper end of its previous revenue guidance ($6.0 to $6.5 million) and gross profit margins for the full year are expected to be in line with previous guidance (at circa. 36%).
Revenue growth from the first half to the second half is supported by volume increases in the EU and North America, increased volumes with cleaning usage in new brands, steady beauty volumes, and growth in hygiene revenues.
John R. Shaw, CEO of Itaconix, commented:
"Our progress in the second half continues to show strong results from our efforts to expand and diversify our customer base with more profitable revenues. Our major investments in new marketing capabilities, new products, additional product studies, global regulatory approvals, better production, and organizational development are starting to pay off with the types of customers and revenues that we want to reach profitability and become a large, highly-attractive specialty ingredients company."